Field Comparison of the Impact of Different Treatment Durations in the Treatment of Acute Otitis Externa

Erik Grandemange, Florence Pillet, Olivier Roy, Frédérique Woehrlé

.
Vétoquinol Research Centre, Lure Cedex, France.

DOI: 10.4236/ojvm.2013.36047                

Abstract

Background: Acute otitis externa is a common multi-factorial disorder in the dog. Several topical preparations are available on the veterinary market, which are licensed for an either specified duration of treatment or for a discretionary period that is determined by the clinician. Objectives: To compare the efficacy of two topical products, both licensed for the treatment of otitis externa in the dog, but with different treatment durations. Animal Population: One hundred and sixty dogs were enrolled in this multicentre field study from which 157 dogs were analysed in the Per Protocol sample (73 Aurizon^?treated animals and 84 Easotic^?treated animals). Method: Dogs were randomly assigned to Aurizon^?or Easotic^?treatment groups. Aurizon^?(Vétoquinol SA: marbofloxacin, clotrimazole, dexamethasone) was administered daily in the affected ear(s) for 7 or 14 days, and was compared with a daily administration of Easotic^?(Virbac SAS: gentamicin, miconazole, hydrocortisone aceponate) for 5 days. General and localised clinical signs were scored on days 0 (D0), 3 (D3), 7 (D7), 14 (D14) and 21 (D21). Results: Clinical cure rates at the end of treatment were 56.3% and 48.8% (p=0.35) in the Aurizon^?and Easotic^?groups respectively and 81.2% versus 74.7% one week after completing the course of treatment (p = 0.34). Twenty-one days after initially presenting for the study, cure rates were 84.3% in the Aurizon^?group and 73.8% in the Easotic^?(p=0.12). A relationship between severity of clinical signs and treatment duration was observed. Conclusion and Clinical Significance: At the end of the trial period, cure rates showed a tendency to be higher in the Aurizon^?treated animals. The flexible dosage and the veterinary monitoring permitted treatment duration to be adjusted based upon the severity of otitis externa thus increasing the likelihood of clinical cure.

Keywords

Acute Otitis Externa; Topical Ear Treatment; Efficacy; Field Clinical Trial

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. Masuda, T. Sukegawa, N. Mizumoto, et al., “Study of Lipid in the Ear Canal in Canine Otitis Externa with Malassezia pachydermatis,” Journal of Veterinary Medical Science, Vol. 62, No. 11, 2000, pp. 1177-1182. http://dx.doi.org/10.1292/jvms.62.1177
[2]	M. Engelen, M. de Bock, J. Hare, et al., “Effectiveness of an Otic Product Containing Miconazole, Polymyxin B and Prednisolone in the Treatment of Canine Otitis Externa: MultiSite Field Trial in the US and Canada,” Journal of Applied Research in Veterinary Medicine, Vol. 8, No. 1, 2010, pp. 21-30.
[3]	R. A. Rosychuk, “Management of Otitis Externa,” Veterinary Clinics of North America: Small Animal Practice, Vol. 24, No. 5, 1994, pp. 921-952.
[4]	H. M. Hayes Jr., L. W. Pickle and G. P. Wilson, “Effects of Ear Type and Weather on the Hospital Prevalence of Canine Otitis Externa,” Research in Veterinary Science, Vol. 42, No. 3, 1987, pp. 294-298.
[5]	E. J. Rosser Jr., “Causes of Otitis Externa,” Veterinary Clinics of North America: Small Animal Practice, Vol. 34, No. 2, 2004, pp. 459-468. http://dx.doi.org/10.1016/j.cvsm.2003.10.006
[6]	J. J. Campbell, K. S. Coyner, S. C. Rankin, et al., “Evaluation of Fungal Flora in Normal and Diseased Canine Ears,” Veterinary Dermatology, Vol. 21, No. 6, 2010, pp. 619-625. http://dx.doi.org/10.1111/j.1365-3164.2010.00927.x
[7]	J. R. August, “Otitis Externa. A Disease of Multifactorial Etiology,” Veterinary Clinics of North America: Small Animal Practice, Vol. 18, No. 4, 1988, pp. 731-742.
[8]	J. J. Kowalski, “The Microbial Environment of the Ear Canal in Health and Disease,” Veterinary Clinics of North America: Small Animal Practice, Vol. 18, No. 4, 1988, pp. 743-754.
[9]	M. N. Saridomichelakis, R. Farmaki, L. S. Leontides, et al., “Aetiology of Canine Otitis Externa: A Retrospective Study,” Veterinary Dermatology, Vol. 18, No. 5, 2007, pp. 341-347. http://dx.doi.org/10.1111/j.1365-3164.2007.00619.x
[10]	H. Zamankhan Malayeri, S. Jamshidi and T. Zahraei Sale-hi, “Identification and Antimicrobial Susceptibility Patterns of Bacteria Causing Otitis Externa in Dogs,” Veterinary Research Communications, Vol. 34, No. 5, 2010, pp. 435-444. http://dx.doi.org/10.1007/s11259-010-9417-y
[11]	L. S. Jacobson, “Diagnosis and Medical Treatment of Otitis Externa in the Dog and Cat,” Journal of the South African Veterinary Association, Vol. 73, No. 4, 2002, pp. 162-170. http://dx.doi.org/10.4102/jsava.v73i4.581
[12]	D. O. Morris, “Medical Therapy of Otitis Externa and Otitis Media,” Veterinary Clinics of North America: Small Animal Practice, Vol. 34, No. 2, 2004, pp. 541-555. http://dx.doi.org/10.1016/j.cvsm.2003.10.009
[13]	G. Lehner, C. Sauter Louis and R. S. Mueller, “Reproducibility in Ear Cytology in Dogs with Otitis Externa,” Veterinary Record, Vol. 167, No. 1, 2010, pp. 23-26. http://dx.doi.org/10.1136/vr.c3523
[14]	E. Bensignor and E. Grandemange, “Comparison of an Antifungal Agent with a Mixture of Antifungal, Antibiotic and Corticosteroid Agents for the Treatment of Malassezia Species Otitis in Dogs,” Veterinary Record, Vol. 158, No. 6, 2006, pp. 193-195. http://dx.doi.org/10.1136/vr.158.6.193
[15]	C. Boda, P. Liege and C. Reme, “Evaluation of Owner Compliance with Topical Treatment of Acute Otitis Externa in Dogs: A Comparative Study of Two Auricular Formulations,” Journal of Applied Research in Veterinary Medicine, Vol. 9, No. 2, 2011, pp. 157-165
[16]	S. Rougier, D. Borell, S. Pheulpin, et al., “A Comparative Study of Two Antimicrobial/Anti-Inflammatory Formulations in the Treatment of Canine Otitis Externa,” Veterinary Dermatology, Vol. 16, No. 5, 2005, pp. 299-307. http://dx.doi.org/10.1111/j.1365-3164.2005.00465.x
[17]	VICH, “International Co-Operation on Harmonisation of Technical Requirements for Registration of Veterinary Medical Products, Good Clinical Practice,” June 2000 effective 01 July 2001. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004343.pdf
[18]	EMA Easotic European Public Assessment Report. www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/veterinary/000140/WC500063875.pdf
[19]	D. Rigaut, A. Sanquer, L. Maynard, et al., “Efficacy of a Topical Ear Formulation with a Pump Delivery System for the Treatment of Infectious Otitis Externa in Dogs: a Randomized Controlled Trial,” Journal of Applied Research in Veterinary Medicine, Vol. 9, No. 1, 2011, pp. 15-28.